

Pharmacy Medical Necessity Guidelines: Ceftin (cefuroxime)

Effective: June 9, 2020

Prior Authorization Required	✓	Type of Review – Care Management	
Not Covered		Type of Review – Clinical Review	✓
Pharmacy (RX) or Medical (MED) Benefit	RX	Department to Review	RXUM
<p>These pharmacy medical necessity guidelines apply to the following:</p> <p>Commercial Products</p> <input type="checkbox"/> Tufts Health Plan Commercial products – large group plans <input type="checkbox"/> Tufts Health Plan Commercial products – small group and individual plans <input type="checkbox"/> Tufts Health Freedom Plan products – large group plans <input type="checkbox"/> Tufts Health Freedom Plan products – small group plans <ul style="list-style-type: none"> CareLinkSM – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization <p>Tufts Health Public Plans Products</p> <input type="checkbox"/> Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product) <input type="checkbox"/> Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans <input checked="" type="checkbox"/> Tufts Health RITogether – A Rhode Island Medicaid Plan		<p>Fax Numbers: RXUM: 617.673.0988</p>	

Note: This guideline does not apply to Medicare Members (includes dual eligible Members).

OVERVIEW

FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS

Ceftin (cefuroxime) is a cephalosporin antibacterial drug indicated for the treatment of the following infections due to susceptible bacteria:

- Pharyngitis/tonsillitis (adults and pediatric patients)
- Acute bacterial otitis media (pediatric patients)
- Acute bacterial maxillary sinusitis (adults and pediatric patients)
- Acute bacterial exacerbations of chronic bronchitis (adults and pediatric patients 13 years and older)
- Uncomplicated skin and skin-structure infections (adults and pediatric patients 13 years and older)
- Uncomplicated urinary tract infections (adults and pediatric patients 13 years and older)
- Uncomplicated gonorrhea (adults and pediatric patients 13 years and older)
- Early Lyme disease (adults and pediatric patients 13 years and older)
- Impetigo (pediatric patients)

Cefuroxime is available in generic tablets (250 mg and 500 mg) and brand suspension (125 mg/5 mL, 250 mg/5 mL). **Generic formulations of cefuroxime are covered and brand suspension requires prior authorization.** The tablets and oral suspension are not bioequivalent and are therefore not substitutable on a milligram-per-milligram basis.

COVERAGE GUIDELINES

The plan may authorize coverage of nonpreferred Ceftin formulations when the following criteria are met:

1. Clinical rationale why Member is not able to administer a generic formulation of cefuroxime.

LIMITATIONS

None

CODES

None

REFERENCES

1. Ceftin (cefuroxime) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2017.

APPROVAL HISTORY

May 9, 2017: Reviewed by Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:

1. July 10, 2018: No changes.
2. August 13, 2019: Administrative changes made to template.
3. Jun 9, 2020: No changes

BACKGROUND, PRODUCT AND DISCLAIMER INFORMATION

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.